Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2017

01-09-2017 | Review

The intriguing connections of leptin to hyperparathyroidism

Authors: Stergios A. Polyzos, Leonidas Duntas, Jens Bollerslev

Published in: Endocrine | Issue 3/2017

Login to get access

Abstract

Purpose

Leptin has been implicated in bone metabolism, but the association with parathyroid gland function has not been fully clarified. This review aimed to summarize evidence of the association between leptin and hyperparathyroidism, both primary and secondary, elucidating the potential pathophysiologic and therapeutic consequences between leptin and parathyroid hormone, hopefully prompting the design of new studies.

Results

Experimental studies indicate a positive loop between leptin and parathyroid hormone in primary hyperparathyroidism. Dissimilar, parathyroid hormone seems to inhibit leptin expression in severe secondary hyperparathyroidism. Data from clinical studies indicate higher leptin levels in patients with primary hyperparathyroidism than controls, but no association between parathyroid hormone and leptin levels, as well as a minimal or neutral effect of parathyroidectomy on leptin levels in patients with primary hyperparathyroidism. Clinical data on secondary hyperparathyroidism, mainly derived from patients with chronic kidney disease, indicate a potential inverse association between leptin and parathyroid hormone in some, but not all studies. This relationship may be affected by the diversity of morbidity among these patients.

Conclusions

Data from experimental studies suggest a different association between leptin and parathyroid hormone in primary and secondary hyperparathyroidism. Data from clinical studies are conflicting and potentially affected by confounders. More focused, well-designed studies are warranted to elucidate a potential association between leptin and parathyroid hormone, which may have specific clinical implications, i.e., targeting obesity and hyperleptinemia in patients with hyperparathyroidism.
Literature
1.
S.A. Polyzos, P. Makras, Z. Efstathiadou, A.D. Anastasilakis, Investigational parathyroid hormone receptor analogs for the treatment of osteoporosis. Exp. Opin. Investig. Drugs 24, 145–157 (2015)CrossRef
2.
3.
A.A. Khan, D.A. Hanley, R. Rizzoli, J. Bollerslev, J.E. Young, L. Rejnmark, R. Thakker, P. D’Amour, T. Paul, S. Van Uum, M.Z. Shrayyef, D. Goltzman, S. Kaiser, N.E. Cusano, R. Bouillon, L. Mosekilde, A.W. Kung, S.D. Rao, S.K. Bhadada, B.L. Clarke, J. Liu, Q. Duh, E.M. Lewiecki, F. Bandeira, R. Eastell, C. Marcocci, S.J. Silverberg, R. Udelsman, K.S. Davison, J.T. Potts Jr., M.L. Brandi, J.P. Bilezikian, Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos. Int. 28, 1–19 (2017)CrossRefPubMed
4.
M.J. Bolland, A.B. Grey, G.D. Gamble, I.R. Reid, Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)CrossRefPubMed
5.
M.A. Adam, B.R. Untch, M.E. Danko, S. Stinnett, D. Dixit, J. Koh, J.R. Marks, J.A. Olson Jr., Severe obesity is associated with symptomatic presentation, higher parathyroid hormone levels, and increased gland weight in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 95, 4917–4924 (2010)CrossRefPubMedPubMedCentral
6.
S.A. Polyzos, C.S. Mantzoros, Leptin in health and disease: facts and expectations at its twentieth anniversary. Metabolism 64, 5–12 (2015)CrossRefPubMed
7.
S.P. Cheng, G.M. Doherty, Y.C. Chang, C.L. Liu, Leptin: the link between overweight and primary hyperparathyroidism? Med. Hypotheses 76, 94–96 (2011)CrossRefPubMed
8.
B.E. Wolfe, D.C. Jimerson, C. Orlova, C.S. Mantzoros, Effect of dieting on plasma leptin, soluble leptin receptor, adiponectin and resistin levels in healthy volunteers. Clin. Endocrinol. 61, 332–338 (2004)CrossRef
9.
M. Dalamaga, S.H. Chou, K. Shields, P. Papageorgiou, S.A. Polyzos, C.S. Mantzoros, Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives. Cell. Metab. 18, 29–42 (2013)CrossRefPubMed
10.
S.A. Polyzos, J. Kountouras, C. Zavos, G. Deretzi, The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J. Clin. Gastroenterol. 45, 50–54 (2011)CrossRefPubMed
11.
S.A. Polyzos, J. Kountouras, C.S. Mantzoros, Leptin in nonalcoholic fatty liver disease: a narrative review. Metabolism 64, 60–78 (2015)CrossRefPubMed
12.
M.A. Tsoukas, O.M. Farr, C.S. Mantzoros, Leptin in congenital and HIV-associated lipodystrophy. Metabolism 64, 47–59 (2015)CrossRefPubMed
13.
M. Karakose, M. Caliskan, M.S. Arslan, T. Demirci, S. Karakose, E. Cakal, The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism. Endocrine 55, 283–288 (2017)CrossRefPubMed
14.
D. Sit, A.K. Kadiroglu, M.E. Yilmaz, I.H. Kara, B. Isikoglu, The prevalence of insulin resistance and its relationship between anemia, secondary hyperparathyroidism, inflammation, and cardiac parameters in chronic hemodialysis patients. Ren. Fail. 27, 403–407 (2005)CrossRefPubMed
15.
H.S. Moon, M. Dalamaga, S.Y. Kim, S.A. Polyzos, O.P. Hamnvik, F. Magkos, J. Paruthi, C.S. Mantzoros, Leptin’s role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr. Rev. 34, 377–412 (2013)CrossRefPubMedPubMedCentral
16.
J. Upadhyay, O.M. Farr, C.S. Mantzoros, The role of leptin in regulating bone metabolism. Metabolism 64, 105–113 (2015)CrossRefPubMed
17.
X.X. Chen, T. Yang, Roles of leptin in bone metabolism and bone diseases. J. Bone. Miner. Metab. 33, 474–485 (2015)CrossRefPubMed
18.
A. Matsunuma, T. Kawane, T. Maeda, S. Hamada, N. Horiuchi, Leptin corrects increased gene expression of renal 25-hydroxyvitamin D3-1 alpha-hydroxylase and -24-hydroxylase in leptin-deficient, ob/ob mice. Endocrinology 145, 1367–1375 (2004)CrossRefPubMed
19.
K. Tsuji, T. Maeda, T. Kawane, A. Matsunuma, N. Horiuchi, Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J. Bone. Miner. Res. 25, 1711–1723 (2010)CrossRefPubMed
20.
I. Lopez, C. Pineda, A.I. Raya, M.E. Rodriguez-Ortiz, J.M. Diaz-Tocados, R. Rios, J.M. Rodriguez, E. Aguilera-Tejero, Y. Almaden, Leptin directly stimulates parathyroid hormone secretion. Endocrine 56, 675–678 (2016)CrossRefPubMed
21.
22.
D. Hoang, N. Broer, J.A. Sosa, N. Abitbol, X. Yao, F. Li, F. Rivera-Molina, D.K. Toomre, S.A. Roman, G. Sue, S. Kim, A.Y. Li, G.G. Callender, C. Simpson, D. Narayan, Leptin is produced by parathyroid glands and stimulates parathyroid hormone secretion. Ann. Surg. (2016). doi:10.​1097/​SLA.​0000000000002004​
23.
Y. Jiang, J. Zhang, Y. Yuan, X. Zha, C. Xing, C. Shen, Z. Shen, C. Qin, M. Zeng, G. Yang, H. Mao, B. Zhang, X. Yu, B. Sun, C. Ouyang, X. Xu, Y. Ge, J. Wang, L. Zhang, C. Cheng, C. Yin, J. Zhang, H. Chen, H. Ma, N. Wang, Association of increased serum leptin with ameliorated anemia and malnutrition in stage 5 chronic kidney disease patients after parathyroidectomy. Sci. Rep. 6, 27918 (2016)CrossRefPubMedPubMedCentral
24.
E. Delfini, L. Petramala, C. Caliumi, D. Cotesta, G. De Toma, G. Cavallaro, G. Panzironi, D. Diacinti, S. Minisola, D.E. E, G.F. Mazzuoli, C. Letizia, Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism. Metabolism 56, 30–36 (2007)CrossRefPubMed
25.
S.K. Bhadada, A. Bhansali, V.N. Shah, D.S. Rao, Changes in serum leptin and adiponectin concentrations and insulin resistance after curative parathyroidectomy in moderate to severe primary hyperparathyroidism. Singapore Med. J. 52, 890–893 (2011)PubMed
26.
D.A. de Luis, G.D. Soto, R. Conde, O. Izaola, B. de la Fuente, Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism. J. Clin. Lab. Anal. 26, 398–402 (2012)CrossRef
27.
D. Hoang, N. Broer, S.A. Roman, X. Yao, N. Abitbol, F. Li, J.A. Sosa, G.R. Sue, A.T. DeWan, M.L. Wong, J. Licinio, C. Simpson, A.Y. Li, N. Pizzoferrato, D. Narayan, Leptin signaling and hyperparathyroidism: clinical and genetic associations. J. Am. Coll. Surg. 218, 1239–1250 (2014). e1234CrossRefPubMed
28.
J. Bollerslev, T. Rosen, C.L. Mollerup, J. Nordenstrom, M. Baranowski, C. Franco, Y. Pernow, G.A. Isaksen, K. Godang, T. Ueland, S. Jansson, S.S. Group, Effect of surgery on cardiovascular risk factors in mild primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2255–2261 (2009)CrossRef
29.
F. Kokot, J. Chudek, H. Karkoszka, M. Adamczak, A. Wiecek, D. Klimek, Does PTH influence leptin concentration in haemodialysed uraemic patients? Nephron 82, 372–373 (1999)CrossRefPubMed
30.
R. Pecoits-Filho, L. Nordfors, O. Heimburger, B. Lindholm, B. Anderstam, A. Marchlewska, P. Stenvinkel, Soluble leptin receptors and serum leptin in end-stage renal disease: relationship with inflammation and body composition. Eur. J. Clin. Invest. 32, 811–817 (2002)CrossRefPubMed
31.
G. Coen, P. Ballanti, M.S. Fischer, A. Balducci, S. Calabria, L. Colamarco, G.Di Zazzo, F. Lifrieri, M. Manni, D. Sardella, I. Nofroni, E. Bonucci, Serum leptin in dialysis renal osteodystrophy. Am. J. Kidney Dis. 42, 1036–1042 (2003)CrossRefPubMed
32.
J. Axelsson, A.R. Qureshi, O. Heimburger, B. Lindholm, P. Stenvinkel, P. Barany, Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD. Am. J. Kidney Dis. 46, 628–634 (2005)CrossRefPubMed
33.
C.P. Kovesdy, M.Z. Molnar, M.E. Czira, A. Rudas, A. Ujszaszi, L. Rosivall, M. Szathmari, A. Covic, A. Keszei, G. Beko, P. Lakatos, J. Kosa, I. Mucsi, Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin. J. Am. Soc. Nephrol. 5, 2297–2304 (2010)CrossRefPubMedCentral
34.
T.A. Ghonemy, E.M. Salim, M. Atia, A. Fekry, K. Shawky, Serum leptin and bone mineral density in hemodialysis patients with or without liver diseases. Arab J. Nephrol. Transplant. 4, 131–136 (2011)CrossRefPubMed
35.
O. Ulutas, H. Taskapan, M.C. Taskapan, I. Temel, Vitamin D deficiency, insulin resistance, serum adipokine, and leptin levels in peritoneal dialysis patients. Int. Urol. Nephrol. 45, 879–884 (2013)CrossRefPubMed
36.
Y. Jiang, Z. Shen, J. Zhang, C. Xing, X. Zha, C. Shen, M. Zeng, G. Yang, H. Mao, B. Zhang, X. Yu, B. Sun, C. Ouyang, Y. Ge, L. Zhang, C. Cheng, J. Zhang, C. Yin, H. Chen, N. Wang, Parathyroidectomy increases heart rate variability and leptin levels in patients with stage 5 chronic kidney disease. Am. J. Nephrol. 44, 245–254 (2016)CrossRefPubMed
37.
A.C. Baxmann, V.B. Menon, J.O. Medina-Pestana, A.B. Carvalho, I.P. Heilberg, Overweight and body fat are predictors of hypovitaminosis D in renal transplant patients. Clin. Kidney J. 8, 49–53 (2015)CrossRefPubMed
38.
J.P. Tsai, M.C. Lee, Y.C. Chen, G.J. Ho, M.H. Shih, B.G. Hsu, Hyperleptinemia is a risk factor for the development of central arterial stiffness in kidney transplant patients. Transplant. Proc. 47, 1825–1830 (2015)CrossRefPubMed
39.
T. Hryszko, S. Brzosko, A. Rydzewska-Rosolowska, E. Koc-Zorawska, B. Naumnik, M. Mysliwiec, Effect of secondary hyperparathyroidism treatment with cinacalcet on selected adipokines and markers of endothelial injury in hemodialysis patients: a preliminary report. Pol. Arch. Med. Wewn. 122, 148–153 (2012)
40.
A. Polymeris, K. Doumouchtsis, E. Grapsa, Bone mineral density and bone metabolism in hemodialysis patients. Correlation with PTH, 25OHD3 and leptin. Nefrologia 32, 73–78 (2012)PubMed
41.
F. Ahmadi, S. Salari, S. Maziar, F. Esfahanian, Z. Khazaeipour, N. Ranjbarnovin, Relationship between serum leptin levels and bone mineral density and bone metabolic markers in patients on hemodialysis. Saudi J. Kidney. Dis. Transpl. 24, 41–47 (2013)CrossRefPubMed
42.
M. Ghorban-Sabbagh, F. Nazemian, M. Naghibi, M.T. Shakeri, S. Ahmadi-Simab, R. Javidi-Dasht-Bayaz, Correlation between serum leptin and bone mineral density in hemodialysis patients. J. Renal. Inj. Prev. 5, 112–117 (2016)CrossRefPubMedPubMedCentral
43.
C. Zoccali, V. Panuccio, G. Tripepi, S. Cutrupi, P. Pizzini, F. Mallamaci, Leptin and biochemical markers of bone turnover in dialysis patients. J. Nephrol. 17, 253–260 (2004)
44.
45.
S.A. Polyzos, K.N. Aronis, J. Kountouras, D.D. Raptis, M.F. Vasiloglou, C.S. Mantzoros, Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 59, 30–43 (2016)CrossRefPubMed
46.
K. Liu, P. Liu, R. Liu, X. Wu, M. Cai, Relationship between serum leptin levels and bone mineral density: a systematic review and meta-analysis. Clin. Chim. Acta. 444, 260–263 (2015)CrossRefPubMed
47.
S.A. Polyzos, J. Kountouras, C.S. Mantzoros, Adipose tissue, obesity and nonalcoholic fatty liver disease. Minerva Endocrinol. (2016) [epub ahead of print]
48.
G. Thomas, A.R. Sehgal, S.R. Kashyap, T.R. Srinivas, J.P. Kirwan, S.D. Navaneethan, Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin. J. Am. Soc. Nephrol. 6, 2364–2373 (2011)CrossRefPubMedPubMedCentral
49.
K.A. Toulis, A.D. Anastasilakis, S.A. Polyzos, P. Makras, Targeting the osteoblast: approved and experimental anabolic agents for the treatment of osteoporosis. Hormones 10, 174–195 (2011)CrossRefPubMed
50.
E.G. Abate, B.L. Clarke, Review of Hypoparathyroidism. Front. Endocrinol. 7, 172 (2016)
51.
J.P. Foo, S.A. Polyzos, A.D. Anastasilakis, S. Chou, C.S. Mantzoros, The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea. J. Clin. Endocrinol. Metab. 99, E2252–E2258 (2014)CrossRefPubMedPubMedCentral
52.
J.D. Christensen, A.O. Lungu, E. Cochran, M.T. Collins, R.I. Gafni, J.C. Reynolds, K.I. Rother, P. Gorden, R.J. Brown, Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy. J. Clin. Endocrinol. Metab. 99, E1493–E1500 (2014)CrossRefPubMedPubMedCentral
53.
T. Harslof, T. Sikjaer, L. Sorensen, S.B. Pedersen, L. Mosekilde, B.L. Langdahl, L. Rejnmark, The effect of treatment with pth on undercarboxylated osteocalcin and energy metabolism in hypoparathyroidism. J. Clin. Endocrinol. Metab. 100, 2758–2762 (2015)CrossRefPubMed
54.
A.L. Schafer, D.E. Sellmeyer, A.V. Schwartz, C.J. Rosen, E. Vittinghoff, L. Palermo, J.P. Bilezikian, D.M. Shoback, D.M. Black, Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J. Clin. Endocrinol. Metab. 96, E1982–E1989 (2011)CrossRefPubMedPubMedCentral
55.
E. Passeri, E. Dozio, M. Mendola, E. Costa, F. Bandera, M.M. Corsi Romanelli, S. Corbetta, Treatment with teriparatide might be associated with cardiometabolic changes in postmenopausal severe osteoporotic women. J. Biol. Regul. Homeost. Agents 29, 931–940 (2015)PubMed
56.
M. Maetani, G. Maskarinec, A.A. Franke, R.V. Cooney, Association of leptin, 25-hydroxyvitamin D, and parathyroid hormone in women. Nutr. Cancer 61, 225–231 (2009)CrossRefPubMedPubMedCentral
Metadata
Title
The intriguing connections of leptin to hyperparathyroidism
Authors
Stergios A. Polyzos
Leonidas Duntas
Jens Bollerslev
Publication date
01-09-2017
Publisher
Springer US
Published in
Endocrine / Issue 3/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1374-6

Other articles of this Issue 3/2017

Endocrine 3/2017 Go to the issue

Original Article

Circulating levels of PTEN and KLLN in papillary thyroid carcinoma: can they be considered as novel diagnostic biomarkers?

Original Article

Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors

Endocrine Methods and Techniques

Total and free cortisol levels during 1 μg, 25 μg, and 250 μg cosyntropin stimulation tests compared to insulin tolerance test: results of a randomized, prospective, pilot study

Research Letter

Circulating neuregulin 4 concentrations in patients with newly diagnosed type 2 diabetes: a cross-sectional study

Original Article

KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment?

Original Article

Autoimmune hypothyroidism is three times more frequent in female prolactinoma patients compared to healthy women: data from a cross-sectional case-control study

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits